Liofilchem, Inc

Neurodex Inc, based in Arlington, MA, is dedicated to advancing precision medicine for neurodegenerative diseases by providing essential biomarkers and technologies to researchers and clinicians. Their mission focuses on improving brain health through the development of blood-based biomarkers that can identify patients with synucleinopathies, including Lewy body dementia, Alzheimer's disease, and Parkinson's disease. Utilizing recent advancements in isolating cell-specific extracellular vesicles, or exosomes, from plasma, Neurodex aims to enhance the diagnosis and treatment of neurological pathologies. The company collaborates with both industry and academia to accelerate the development and approval of effective blood tests and therapies. Generated from the website

Volatylix, Inc., based in Cambridge, MA, is committed to fostering innovation and entrepreneurship in the United States through its involvement in the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. These initiatives provide non-dilutive funding to small businesses and startups, enabling them to develop and commercialize their technological solutions while maintaining ownership of their equity and intellectual property. Every year, America's Seed Fund invests approximately $4 billion, supporting around 4,000 companies in their pursuit of scientific and technological advancements. With a strong focus on job creation and economic impact, the program has added over 65,000 jobs to the U.S. economy annually, highlighting its crucial role in driving innovation and addressing federal research and development needs. Generated from the website

Headquartered in Cambridge, Mass., Biogen Idec specializes in the field of biotechnology. Its core capabilities include drug discovery, research and development. The company s focus is the development of products related to oncology, neurology and immunology. Among the company s products are treatments for B-cell, non-Hodgkin s lymphomas; a treatment for relapsing forms of multiple sclerosis; and a treatment for psoriasis and psoriatic arthritis. In addition, the company has several licensed and dedicated bulk-manufacturing facilities engaged in protein manufacturing. James C. Mullen has been the chief executive officer of Biogen Indec for more than two years. He has been with the drug and biotechnology company for over 17 years. Mullen earned a BS degree from Rensselaer Polytech, and a MBA from Villanova. The company maintains research centers in Cambridge, Mass., and San Diego. Biogen Idec has additional offices in Canada, Australia, Japan and Europe, including international headquarters in Zug, Switzerland. The company currently employs approximately 3,400 people worldwide.